Myriad’s myChoice CDx bags FDA approval for treatment with Zejula
Category: #health  | By Mateen Dalal  | Date: 2019-10-25 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Myriad’s myChoice CDx bags FDA approval for treatment with Zejula

Ovarian cancer is termed as fifth most common cause of cancer-related death among women in the U.S. It can mostly be treated by surgery or chemotherapy; however, several biotech companies are now making some groundbreaking innovation for developing novel therapies for this disease.

Myriad Genetics, Inc., a leading producer of precision medicine and molecular diagnostics, recently made some strides in this sector when it revealed that the U.S. FDA (Food and Drug Administration) has approved its myChoice® CDx to be used as a companion diagnostic by medical specialists to detect women with last-stage ovarian cancer. It will be used on patients that are candidates of Zejula® (niraparib) in a late-line treatment setting.

Reportedly, GlaxoSmithKline has also obtained an approval from the FDA, allowing it to conduct an expanded indication for Zejula while treating advanced fallopian tube, primary peritoneal or ovarian cancer patients, who were previously treated with multiple chemotherapy regimens and whose cancer is classified in terms of homologous recombination deficiency.  

Speaking on the development, Jerry Lanchbury, Ph.D., Chief Scientific Officer, Myriad, said that the company congratulates GlaxoSmithKline for attaining an approval from the FDA for Zejula. Moreover, the recent FDA nod marks as a significant landmark for their company’s latest therapy myChoice CDx which took over 10 years to develop

Lanchbury added that this achievement showcases the company’s commitment to revolutionary science and partnership with pharmaceutical partners, to advance precision therapies for patients going through cancer.

Earlier this year, Myriad had made headlines when it had announced a change in its management. Apparently, the pharmaceutical firm had appointed Mark H. Pollack, M.D., as the new chief medical officer of its Neuroscience division and will start with his role from Jan. 15, 2020.  

According to Myriad, Dr. Pollack will contribute in making GeneSight a standard-of-care drug in clinical practice and will be reporting to President of Myriad Neuroscience, Mark Verratti. 

Source Credit: https://myriad.com/investors/news-release/news-release-detail/?newsItemId=20741

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted

Microsoft investigates Teams and Outlook outage that left users disrupted

By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

By Mateen Dalal

Britishers who rely on the budget-friendly aisles of supermarkets reportedly saw the biggest increases in food prices in the months leading up to Christmas, significantly outpacing those for luxury as well as premium brands, as per a survey. Accor...

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

By Mateen Dalal

Sun Cable, the Singapore-based solar energy company, has reportedly entered voluntary administration, despite the financial support it received from billionaire investors. The company was supposed to be working on a A$30 billion (US$21 billion) solar...